Active Investigational Treatment ENT-01

DRUG3 trials

Sponsors

Enterin Inc.

Conditions

ConstipationDementiaParkinson Disease

Phase 1

A Study to Evaluate ENT-01 for the Treatment of Parkinson's Disease Dementia

WithdrawnNCT03938922

Enterin Inc.Dementia, Parkinson Disease

Start: 2024-03-01End: 2025-12-15Updated: 2024-03-01

Phase 2

Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET)

CompletedNCT03781791

Enterin Inc.Constipation, Parkinson Disease

Start: 2018-12-10End: 2021-12-14Updated: 2024-02-20

Orally Administered ENT-01 for Parkinson's Disease-Related Constipation Follow-on Safety Roll-over Study (Rollover)

TerminatedNCT04483479

Enterin Inc.Constipation, Parkinson Disease

Start: 2020-07-30End: 2022-02-17Updated: 2024-03-19

Related Papers

Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease : A Randomized Controlled Trial.

2022-11-0838 citations